Pathophysiology, clinical presentation and treatment of gout

Drugs

Volumn 66, Issue 12, 2006, Pages 1547-1563

  Teng, Gim Gee ^a   Nair, Raj ^a   Saag, Kenneth G ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMPICILLIN; AZATHIOPRINE; COLCHICINE; CORTICOTROPIN; CYCLOSPORIN A; DAPSONE; ETORICOXIB; FEBUXOSTAT; GLUCOCORTICOID; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; MACROLIDE; MERCAPTOPURINE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PENICILLIN G; PREDNISONE; PROBENECID; PURINE; RIFAMPICIN; SALICYLIC ACID; TETRACOSACTIDE; URATE OXIDASE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ALCOHOL CONSUMPTION; ARTHRITIS; BONE MARROW SUPPRESSION; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIET; DISEASE ASSOCIATION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPEPSIA; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; KIDNEY DYSFUNCTION; LEUKOPENIA; MULTIPLE ORGAN FAILURE; NEPHROLITHIASIS; NEUROMUSCULAR DISEASE; NEUTROPENIA; OSTEOPOROSIS; PANCYTOPENIA; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PURINE METABOLISM; RASH; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STOMACH DISEASE; TREATMENT FAILURE; URIC ACID URINE LEVEL; WEIGHT GAIN;

ACUTE DISEASE; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLCHICINE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PURINES; RISK FACTORS;

EID: 33748611626     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666120-00002     Document Type: Review

References (125)

1. Mikuls T, Farrar J, Bilker W, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005; 44: 1038-42
2. Mikuls TR, Curtis JR, Allison JJ, et al. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol 2006 Mar; 33 (3): 562-6
3. Breckenridge A. Hypertension and hyperuricaemia. Lancet 1966 Jan 1; 1 (7427): 15-8
4. Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005 Apr 11; 165 (7): 742-8
5. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995 Apr 1; 141 (7): 637-44
6. Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994 Jan; 78 (1): 25-9
7. Mikuls T, MacLean C, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004; 50: 937-43
8. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002 Jul; 40 (1): 37-42
9. Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am 1990; 16: 539-50
10. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995 Sep; 48 (9): 1153-8
11. Klemp P, Stansfield SA, Castle B, et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997 Jan; 56 (1): 22-6
12. Centers for Disease Control and Prevention, National Center for Health Statistics. Vital and health statistics: current estimates from the National Health Interview Survey, 1996. Series 10. No. 200 [online]. Atlanta (GA): Department of Health and Human Services (US). Available from URL: http://www.cdc.gov/nchs/data/series/sr_10/sr10_200.pdf [Accessed 2006 Aug 14]
13. Wallace K, Riedel A, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: 1582-7
14. Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988; 41 (3): 237-42
15. Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases: 4. Gout. Br J Rheumatol 1990 Dec; 29 (6): 485-8
16. Arromdee E, Michet C, Crowson C, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29: 2403-6
17. Mikuls T, Farrar J, Bilker W, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-72
18. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987 Mar; 82 (3): 421-6
19. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002 May; 14 (3): 281-6
20. Choi H, Atkinson K, Karlson E, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-103
21. Choi H, Atkinson K, Karlson E, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277-81
22. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005 Jan; 52 (1): 283-9
23. Gibson T, Rodgers A, Simmonds H, et al. Beer drinking and its effect on uric acid. Br J Rheumatol 1984; 23: 203-9
24. Puig JG, Fox IH. Ethanol-induced activation of adenine nucleotide turnover: evidence for a role of acetate. J Clin Invest 1984 Sep; 74 (3): 936-41
25. Eastmond CJ, Garton M, Robins S, et al. The effects of alcoholic beverages on urate metabolism in gout sufferers. Br J Rheumatol 1995 Aug; 34 (8): 756-9
26. Faller J, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med 1982 Dec 23; 307 (26): 1598-602
27. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000 Apr; 27 (4): 1045-50
28. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002 May 23; 417 (6887): 447-52
29. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000 Jan; 43 (1): 103-8
30. Marcen R, Gallego N, Orofino L, et al. Influence of cyclosporin A (CyA) on renal handling of urate. Transpl Int 1992; 5 Suppl. 1: S81-3
31. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000 May; 11 (5): 974-9
32. Niamane R, El Hassani S, Bezza A, et al. Lead-related gout: a case report. Joint Bone Spine 2002 Jun; 69 (4): 409-11
33. Ball G, Sorensen L. Pathogenesis of hyperuricemia in saturinine gout. N Engl J Med 1969; 280 (22): 1199-202
34. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004 Aug; 50 (8): 2400-14
35. Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan: influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004 Jan; 15 (1): 164-73
36. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti Heart Study. J Hum Hypertens 1994 Sep; 8 (9): 677-81
37. Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003 Oct; 42 (4): 474-80
38. Selby JV, Friedman GD, Quesenberry CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990 Jun; 131 (6): 1017-27
39. Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001 Jul; 19 (7): 1209-15
40. Sundstrom J, Sullivan L, D'Agostino R, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33
41. Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002 Nov; 283 (5): F1105-10
42. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid in creases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001 Nov; 38 (5): 1101-6
43. Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004 Jul; 66 (1): 281-7
44. Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001 Nov; 24 (6): 691-7
45. Reif MC, Constantiner A, Levitt MF. Chronic gouty nephropathy: a vanishing syndrome? N Engl J Med 1981 Feb 26; 304 (9): 535-6
46. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002 Dec; 13 (12): 2888-97
47. Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med 1978 May; 88 (5): 666-70
48. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 Jan 16; 287 (3): 356-9
49. Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998 May; 8 (4): 250-61
50. Becker M, Jolly M. Clinical gout and the pathogenesis of hyperuricemia. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Baltimore (MA): Williams & Wilkins, 2005: 2303-39
51. Emmerson BT. The management of gout. N Engl J Med 1996 Feb 15; 334 (7): 445-51
52. Simkin PA. Uric acid excretion in patients with gout. Arthritis Rheum 1979 Jan; 22 (1): 98-9
53. McPhaul JJ. Hyperuricemia and urate excretion in chronic renal disease. Metabolism 1968 May; 17 (5): 430-8
54. Michet CJ, Evans JM, Fleming KC, et al. Common rheumatologic diseases in elderly patients. Mayo Clin Proc 1995 Dec; 70 (12): 1205-14
55. Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis 1970 Sep; 29 (5): 461-8
56. Scott JT. Drug-induced gout. Baillieres Clin Rheumatol 1991 Apr; 5 (1): 39-60
57. Pascual E, Batlle-Gualda E, Martinez A, et al. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999 Nov 16; 131 (10): 756-9
58. Nakayama DA, Barthelemy C, Carrera G, et al. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984 Apr; 27 (4): 468-71
59. O'Duffy JD, Hunder GG, Kelly PJ. Decreasing prevalence of tophaceous gout. Mayo Clin Proc 1975 May; 50 (5): 227-8
60. Schumacher H. Crystal-induced arthritis: an overview. Am J Med 1996; 100: S46-52
61. Rott KT, Agudelo CA. Gout. JAMA 2003 Jun 4; 289 (21): 2857-60
62. Puig JG, Michan AD, Jimenez ML, et al. Female gout: clinical spectrum and uric acid metabolism. Arch Intern Med 1991 Apr; 151 (4): 726-32
63. Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis 1997 Nov; 56 (11): 696-7
64. Simkin PA, Hoover PL, Paxson CS, et al. Uric acid excretion: quantitative assessment from spot, midmorning serum and urine samples. Ann Intern Med 1979 Jul; 91 (1): 44-7
65. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001 Mar; 28 (3): 577-80
66. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002 Aug; 47 (4): 356-60
67. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005 Oct 4; 143 (7): 499-516
68. Fam A. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002; 29: 1350-5
69. Dessein P, Shipton E, Stanwix A, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539-43
70. Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004 Nov; 71 (6): 481-5
71. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004 Mar; 65 (3): 1041-9
72. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64 (21): 2399-416
73. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout: part ii management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006 May 30 [Epub ahead of print]
74. Altman RD, Honig S, Levin JM, et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988 Sep; 15 (9): 1422-6
75. Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995 Dec; 26 (6): 682-6
76. Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992 Sep 10; 327 (11): 749-54
77. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991 Aug 1; 115 (3): 165-72
78. Schumacher HR, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002 Jun 22; 324 (7352): 1488-92
79. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520-8
80. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 Mar 17; 352 (11): 1071-80
81. Fox IH, Kelley WN. Management of gout. JAMA 1979 Jul 27; 242 (4): 361-4
82. Bonnel RA, Villalba ML, Karwoski CB, et al. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002 May; 22 (4): 385-7
83. Sussman JS, Brozena SC, Skop N, et al. Accidental intravenous colchicine poisoning. Ther Drug Monit 2004 Dec; 26 (6): 688-92
84. Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy: classical indications and new therapeutic uses. Eur J Med Res 2001 Apr 20; 6 (4): 150-60
85. Roberts W, Liang M, Stern S. Colchicine in acute gout. Reassessment of risks and benefits. JAMA 1987; 257 (14): 1920-2
86. Wallace S, Singer J. Review: systemic toxicity associated with the IV administration of colchicine: guidelines for use. J Rheumatol 1988; 15 (3): 495-9
87. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990 Jun; 19 (6): 329-36
88. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994 Jul; 21 (7): 1325-7
89. Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2001 Mar; 35 (3): 365-8
90. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988 Jun; 31 (6): 803-5
91. Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994 Apr; 21 (4): 696-9
92. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987 Jun; 17 (3): 301-4
93. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004 Dec; 31 (12): 2429-32
94. Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004 Dec; 24 (12): 1784-92
95. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004 Jun 15; 51 (3): 321-5
96. van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of long-term antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993 Aug; 20 (8): 1383-5
97. Day RO, Miners JO, Birkett DJ, et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988 Oct; 26 (4): 423-8
98. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hypercaemia: a pathogenic approach to the treatment of primary urichronic gout. Ann Rheum Dis 1998 Sep; 57 (9): 545-9
99. Takada M, Okada H, Kotake T, et al. Appropriate dosing regimen of allopurinol in Japanese patients. J Clin Pharm Ther 2005 Aug; 30 (4): 407-12
100. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004 Aug; 31 (8): 1575-81
101. Hande K, Noone R, Stone W. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56
102. Fam AG, Dunne SM, Iazzetta J, et al. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001 Jan; 44 (1): 231-8
103. Walz-LeBlanc BA, Reynolds WJ, MacFadden DK. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum 1991 Oct; 34 (10): 1329-31
104. US Food and Drug Administration. Cumulative list of orphan products designated through 2006 [online]. Available from URL: http://www.fda.gov/orphan/ designat/alldes.rtf [Accessed 2006 Aug 14]
105. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005 May; 17 (3): 319-24
106. Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol 1993 Dec 21; 250 (3): 455-60
107. Hoshide S, Takahashi Y, Ishikawa T, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004 Oct; 23 (8-9): 1117-8
108. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005 Jan-Feb; 12 (1): 22-34
109. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 Dec 8; 353 (23): 2450-61
110. Goldman SC. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 2003 Aug; 3 (4): 429-33
111. Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003 Jul-Aug; 37 (7-8): 1047-54
112. Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002 Sep; 29 (9): 1942-9
113. Nishimura H, Matsushima A, Inada Y. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. Enzyme 1981; 26 (1): 49-53
114. Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly (ethylene) glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2005 Dec 2; 8 (1): R12
115. Sundy JS, Becker MA, Baraf HB, et al. A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and refractory gout. Arthritis Rheum 2005; 52 (9): S257-S8
116. Lin HY, Rocher LL, McQuillan MA, et al. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989 Aug 3; 321 (5): 287-92
117. Hansen JM, Fogh-Andersen N, Leyssac PP, et al. Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A. Nephron 1998 Dec; 80 (4): 450-7
118. Delaney V, Sumrani N, Daskalakis P, et al. Hyperuricemia and gout in renal allograft recipients. Transplant Proc 1992 Oct; 24 (5): 1773-4
119. el-Gamel A, Evans C, Keevil B, et al. Effect of allopurinol on the metabolism of azathioprine in heart transplant patients. Transplant Proc 1998 Jun; 30 (4): 1127-9
120. McLean L. Gout in transplant recipients. In: Hochberg MC, Silman AJ, Smolen JS, et al., editors. Rheumatology. Edinburgh: Elsevier, 2003: 1914
121. Gibson T. Gout in older people. In: Hochberg MC, Silman AJ, Smolen JS, et al., editors. Rheumatology. Edinburgh: Elsevier Limited, 2003: 1926
122. Fam A. Gout in the elderly: clinical presentation and treatment. Drugs Aging 1998; 13: 229-43
123. Dieppe PA. Investigation and management of gout in the young and the elderly. Ann Rheum Dis 1991 Apr; 50 (4): 263-6
124. Terkeltaub RA. Clinical practice: gout. N Engl J Med 2003 Oct 23; 349 (17): 1647-55
125. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001 Oct; 60 (10): 981-3